This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
New Approaches to the Treatment of Hepatitis C Virus Infection

New Approaches to the Treatment of Hepatitis C Virus Infection


Slide Lecture Series

Time to Complete

1.50 hours


May 22, 2017


May 22, 2018
Add to Queue

Maximum Credits

1.50 / AMA PRA Category 1 CreditsTM

Pharmacy Credits

Pharmacists may earn 1.50 CPE Credits (0.15 CEUs) by completing this course on the American Society of Health-System Pharmacists (ASHP) website. Please click here to go to the course (you will leave the myCME website and need to register/sign in on the ASHP site). Your certificate will save on and will not be included in your myCME CME History.

Accredited Provider

This continuing medical education activity is provided by the American Society of Health-System Pharmacists (ASHP).

Commercial Supporter

Supported by an educational grant from Merck

Program Description

The management of hepatitis C virus (HCV) infection has evolved quickly since the introduction of direct-acting antiviral agents (DAAs) in 2011. Current treatment options include several DAA combination regimens and each has been associated with achieving sustained virologic response (SVR), or HCV cure. Achieving SVR decreases mortality and reduces a patient’s risk of HCV-related complications, including decompensated cirrhosis and hepatocellular carcinoma. According to current treatment guidelines, achieving SVR is the goal for all patients who receive HCV treatment. While the pace of change in the field of HCV medicine remains rapid and effective, treatment options continue to emerge and challenges remain for clinicians in achieving SVR for all patients. This is particularly true of certain patient populations who have advanced HCV disease, have failed previous HCV treatment, or have concomitant conditions that can complicate treatment such as HIV co-infection or renal insufficiency.

This program will apply emerging evidence and current practice guidelines to address the contemporary challenges in achieving SVR in all patients with HCV, including those who are difficult to treat. Case studies demonstrating new approaches to managing patients with HCV infection will be discussed and the program will emphasize the importance of collaboration among healthcare professionals, including physicians and pharmacists, in order to achieve optimal patient outcomes.

Intended Audience

This continuing education activity was planned to meet the needs of pharmacists and physicians in a variety of practice settings, including large and small healthcare settings, ambulatory care clinics, managed care organizations, and academia. The activity is particularly beneficial for pharmacists and physicians who are interested in treating patients with hepatitis C virus infection.

Educational Objectives

At the conclusion of this application-based educational activity, participants should be able to:

  • Discuss the current epidemiology and burden of disease associated with HCV infection
  • Evaluate current and emerging treatment options for the management of patients with HCV infection
  • Apply guidelines and study data to determine appropriate treatment strategies for HCV infected patients who are harder to treat

Conflict Of Interest Disclosure Policy

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support and the Accreditation Council for Pharmacy Education’s Standards for Commercial Support, ASHP requires that all individuals involved in the development of activity content disclose their relevant financial relationships. A person has a relevant financial relationship if the individual or his or her spouse/partner has a financial relationship (e.g. employee, consultant, research grant recipient, speakers bureau, or stockholder) in any amount occurring in the last 12 months with a commercial interest whose products or services may be discussed in the educational activity content over which the individual has control. The existence of these relationships is provided for the information of participants and should not be assumed to have an adverse impact on the content.

All faculty and planners for ASHP education activities are qualified and selected by ASHP and required to disclose any relevant financial relationships with commercial interests. ASHP identifies and resolves conflicts of interest prior to an individual’s participation in development of content for an educational activity. Anyone who refuses to disclose relevant financial relationships must be disqualified from any involvement with a continuing pharmacy education activity.


Jason J. Schafer, PharmD, MPH, BCPS, AAHIVP, Activity Chair
Associate Professor, Department of Pharmacy Practice
Jefferson College of Pharmacy
Clinical Pharmacy Specialist, HIV Ambulatory Care
Jefferson Infectious Diseases Associates
Thomas Jefferson University
Philadelphia, PA

Dr. Schafer declares he received a research grant from Merck.

William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA

Dr. Short declares he is a consultant and on the speakers bureau for Gilead Sciences.

Planners' and Managers' Disclosures

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.


In order to receive credit, participants must complete the post-test and program evaluation. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue